A Trial to Learn How Well Linvoseltamab works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants with Relapsed/Refractory Multiple Myeloma LINKER-MM3
Verified

What's the purpose of this trial?

The aim of this study is to see how safe and effective linvoseltamab is compared to a combination of three cancer drugs: elotuzumab, pomalidomide and dexamethasone, (called EPd) in participants who have returned after having received prior treatment that included lenalidomide, a proteasome inhibitor, and (for participants in some countries) a cluster of differentiation 38 (CD38) antibody.

This trial is currently open and accepting patients.

What will happen during the trial?

This clinical trial is seeking approximately 380 participants. This is a Phase 3 trial that is randomized and open-label. Randomized means that the treatment each participant receives will be randomly assigned by a computer program. Open-label means that both the participants and the trial doctors will know what treatment the participants are receiving. Participants will be screened up to 28 days before the trial and then participate in the trial for as long as they are receiving benefit or until they leave the trial for another reason.

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

  • have measurable disease as described by the trial criteria.
  • have received at least one and no more than four prior lines of therapy.
  • have not previously received treatment with elotuzumab or pomalidomide.
  • do not have central nervous system involvement of your myeloma.
  • have not had an allogeneic transplant in the last 6 months, or an autologous transplant in the last 3 months before joining this study.
  • have not previously received treatment with BCMA directed therapy (BCMA antibody drug conjugates are allowed).
  • Have adequate major organ function as described by the trial criteria.

Additional Trial Information

Phase 3

Enrollment: 380 patients (estimated)

View More
Need Help?

Interested in joining or learning more about this trial?

(888) 828-2206

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

California

UCLA Medical Center of Hematology/Oncology

Los Angeles, CA

Open and Accepting

Kentucky

UK Markey Cancer Center University of Kentucky

Lexington, KY

Open and Accepting

Norton Cancer Institute (St. Matthews) St. Matthews Campus

Louisville, KY

Open and Accepting

New York

Stony Brook University Hospital

Stony Brook, NY

Open and Accepting

North Carolina

Atrium Health's Levine Cancer Institute - Charlotte (Main) Atrium Health

Charlotte, NC

Open and Accepting

Duke Cancer Center Duke University Medical Center

Durham, NC

Open and Accepting

Oregon

Kaiser Permanente Northwest

Portland, OR

Open and Accepting

Texas

MD Anderson Cancer Center The University of Texas

Houston, TX

Open and Accepting

Washington

Fred Hutchinson Cancer Research Center University of Washington Cancer Consortium / SCCA

Seattle, WA

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • Add this trial to your favorites keyboard_arrow_right

    If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

Learn more about how we work with trial sponsors